Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 15:59:58 01/07/2024 BST 5-day change 1st Jan Change
1,005 DKK -0.10% Intraday chart for Novo Nordisk A/S +1.64% +43.90%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
India panel urges drug regulator to approve Lilly's obesity drug Mounjaro RE
New semester, new state of mind Our Logo
India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
NOVO NORDISK : UBS gives a Neutral rating ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot MT
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says MT
NOVO NORDISK : JP Morgan gives a Buy rating ZD
The same old winners Our Logo
NOVO NORDISK : Goldman Sachs reiterates its Buy rating ZD
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million DJ
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Sector Update: Health Care MT
European Equities Close Lower in Wednesday Trading MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected MT
Novo Nordisk: trial failure and impact on results CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial MT
Novo Nordisk makes impairment loss of $816 million in Q2 RE
AlphaValue/Baader Europe Downgrades Novo Nordisk to Add from Buy, Raises PT MT
China Approves Novo Nordisk's Injection for Long-term Weight Management MT
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk May Pay Up to $600 Million in New Obesity R&D Deal